Targeting the Hyperglycemic Pre‐Metastatic Niche to Prevent Breast Cancer Bone Metastasis: Mechanisms and Therapeutic Strategies

Abstract The recent pioneering study by Ye et al. (Adv Sci. 2025;12(37):e0504924) provides compelling evidence that systemic hyperglycemia orchestrates a pre‐metastatic niche (PMN) in bone, promoting breast cancer metastasis and identifying Receptor for Advanced Glycation End‐products (RAGE) inhibition as a viable therapeutic strategy. While this work represents a significant conceptual advance by linking systemic metabolism to organotropic metastasis, the analysis identifies several substantive challenges that must be addressed to translate this finding into clinical practice. First, the authors clarify that the primary driver of enhanced bone metabolism is likely tumor‐derived educative signals, with hyperglycemia acting as a secondary sensitizer rather than a sole instigator; this hierarchical causality requires further dissection. Second, the pleiotropic roles of RAGE in physiology and immunity raise concerns about the potential for on‐target, adverse effects with long‐term inhibition, necessitating the development of more targeted approaches. Finally, while the primary metabolic therapy proposed is GP‐mediated glucose deprivation, the therapeutic efficacy demonstrated in a preventative model requires validation in scenarios of established micro‐metastases, which mirror the clinical reality more closely. This critical appraisal underscores the need for a more nuanced understanding of the niche's biology and a rigorous evaluation of the proposed therapeutic paradigm's safety and timing. Abstract The recent pioneering study by Ye et al. (Adv Sci. 2025;12(37):e0504924) provides compelling evidence that systemic hyperglycemia orchestrates a pre-metastatic niche (PMN) in bone, promoting breast cancer metastasis and identifying Receptor for Advanced Glycation End-products (RAGE) inhibition as a viable therapeutic strategy. While this work represents a significant conceptual advance by linking systemic metabolism to organotropic metastasis, the analysis identifies several substantive challenges that must be addressed to translate this finding into clinical practice. First, the authors clarify that the primary driver of enhanced bone metabolism is likely tumor-derived educative signals, with hyperglycemia acting as a secondary sensitizer rather than a sole instigator; this hierarchical causality requires further dissection. Second, the pleiotropic roles of RAGE in physiology and immunity raise concerns about the potential for on-target, adverse effects with long-term inhibition, necessitating the development of more targeted approaches. Finally, while the primary metabolic therapy proposed is GP-mediated glucose deprivation, the therapeutic efficacy demonstrated in a preventative model requires validation in scenarios of established micro-metastases, which mirror the clinical reality more closely. This critical appraisal underscores the need for a more nuanced understanding of the niche's biology and a rigorous evaluation of the proposed therapeutic paradigm's safety and timing. Advanced Science, EarlyView.